Skip to main content
. 2023 Jun 9;22(7):100590. doi: 10.1016/j.mcpro.2023.100590

Figure 5.

Figure 5

Cystatin A detection from patient derived tampons.A, feature intensity as measured by MALDI-TOF mass spectrometry (MS) of m/z 11,007 (cystatin A) in protein profiles from six patient-derived tampon extracts following preprocessing and outlier removal. A comparison between benign and ovarian cancer extracts using Welch’s two-sample t test provided mean intensities of 0.0018 for benign cancer and 0.0034 for ovarian cancer (p < 1.07e-07; 95% confidence interval = [−0.0021, −0.0010]). B, label-free detection of cystatin A from patient-derived tampon extracts using a microtoroid resonator. We observe that the amount of cystatin A as measured by MALDI-TOF MS protein profiling agrees with measurements via FLOWER (frequency-locked optical whispering evanescent resonator).